Fluorescent cell-traceable dexamethasone-loaded liposomes for the treatment of inflammatory liver diseases

Bartneck, Matthias; Scheyda, Katharina M.; Warzecha, Klaudia Theresa; Rizzo, Larissa Yokota; Hittatiya, Kanishka; Luedde, Tom; Storm, Gert; Trautwein, Christian; Lammers, Twan; Tacke, Frank

doi:10.1016/j.biomaterials.2014.10.030

Cited by 122 publications

(99 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A drawback of this approach is the systemic immunosuppression which makes it also technically difficult to determine which cells have been targeted. Recent studies using models of acute and chronic experimental injury have shown that DEX-loaded liposomes compared to free DEX may be a more efficient tool not only to target macrophages but also to modulate their inflammatory cytokine responses and their migratory properties2526. In our experiments, DEX did affect ALT levels in DDC-treated mice, nonetheless it still dimished bilirubin levels and decreased collagen and laminin deposition and CK19 + cell expansions.…”

Section: Discussionmentioning

confidence: 42%

Infliximab and Dexamethasone Attenuate the Ductular Reaction in Mice

Verhulst

Best

Syn

et al. 2016

Sci Rep

View full text Add to dashboard Cite

Chronic hepatic injury is accompanied by a ductular response that is strongly correlated with disease severity and progression of fibrosis. To investigate whether anti-inflammatory drugs can modulate the ductular response, we treated mice suffering from a steatotic or cholestatic injury with anti-TNF-α antibodies (Infliximab) or glucocorticoids (Dexamethasone). We discovered that Dexamethasone and Infliximab can both modulate the adaptive remodeling of the biliary architecture that occurs upon liver injury and limit extracellular matrix deposition. Infliximab treatment, at least in these steatotic and cholestatic mouse models, is the safer approach since it does not increase liver injury, allows inflammation to take place but inhibits efficiently the ductular response and extracellular matrix deposition. Infliximab-based therapy could, thus, still be of importance in multiple chronic liver disorders that display a ductular response such as alcoholic liver disease or sclerosing cholangitis.

show abstract

Section: Discussionmentioning

confidence: 42%

Infliximab and Dexamethasone Attenuate the Ductular Reaction in Mice

Verhulst

Best

Syn

et al. 2016

Sci Rep

View full text Add to dashboard Cite

show abstract

“…These NPs are proven to target hepatic macrophages by reducing T cells in the liver through an immune reaction, which results in the reduction of liver inflammation and fibrosis. 52 Another group reported cationic liposomes bearing microbubbles for the effective delivery of artificial microRNA, which was used to target connective tissue growth factor (CTGF) and can be useful for the inhibition of hepatic fibrosis. In their study, the ultrasound-mediated bubble destruction gene delivery of artificial microRNA in a dimethyl nitrosamine-induced fibrotic mouse model resulted in a decrease in fibrotic marker collagen, as well as α-SMA, by targeting CTGF.…”

Section: Liposomesmentioning

confidence: 99%

Nanoparticles for the treatment of liver fibrosis

Surendran¹,

Thomas²,

Moon³

et al. 2017

IJN

114

View full text Add to dashboard Cite

Chronic liver diseases represent a global health problem due to their high prevalence worldwide and the limited available curative treatment options. They can result from various causes, both infectious and noninfectious diseases. The application of nanoparticle (NP) systems has emerged as a rapidly evolving area of interest for the safe delivery of various drugs and nucleic acids for chronic liver diseases. This review presents the pathogenesis, diagnosis and the emerging nanoparticulate systems used in the treatment of chronic liver diseases caused by liver fibrosis. Activated hepatic stellate cell (HSC) is considered to be the main mechanism for liver fibrosis. Ultrasonography and magnetic resonance imaging techniques are widely used noninvasive diagnostic methods for hepatic fibrosis. A variety of nanoparticulate systems are mainly focused on targeting HSC in the treatment of hepatic fibrosis. As early liver fibrosis is reversible by current NP therapy, it is being studied in preclinical as well as clinical trials. Among various nanoparticulate systems, inorganic NPs, liposomes and nanomicelles have been widely studied due to their distinct properties to deliver drugs as well as other therapeutic moieties. Liposomal NPs in clinical trials is considered to be a milestone in the treatment of hepatic fibrosis. Currently, NP therapy for liver fibrosis is updating fast, and hopefully, it can be the future remedy for liver fibrosis.

show abstract

“…In this property of theirs, phospholipids are useful to construct artificial biological delivery systems or even the membranes of artificial cells. Using phospholipids as main component of biological membranes, lipids are useful to design fully biocompatible drug delivery systems . Some lipids do also have biological activity, such as the prostaglandins, features which might in future be adopted by lipid‐based drugs or NM.…”

Section: Introductionmentioning

confidence: 99%

Immunomodulatory Nanomedicine

Bartneck

2017

Macromolecular Bioscience

Self Cite

View full text Add to dashboard Cite

Immunity has a major impact on inflammatory diseases and cancer, and biologics targeting immune cells and their factors reach a quarter trillion of market volume by this year. Adaptive leukocytes have recently been engaged in cancer immunotherapy, whereas modulation of the innate immune cells, specifically macrophages, is expected as next breakthrough. With patents of major biologics expiring, nanomedicine has the potential to substitute therapeutic proteins by using miniaturized macromolecules. This review includes an overview on the involvement of major immune cell types into disease and a summary on selected current therapies based on biologics and small molecules. Novel developments in nanomedicine‐based immunotherapies, including associated chances and risks, are presented.

show abstract

Fluorescent cell-traceable dexamethasone-loaded liposomes for the treatment of inflammatory liver diseases

Cited by 122 publications

References 35 publications

Infliximab and Dexamethasone Attenuate the Ductular Reaction in Mice

Infliximab and Dexamethasone Attenuate the Ductular Reaction in Mice

Nanoparticles for the treatment of liver fibrosis

Immunomodulatory Nanomedicine

Contact Info

Product

Resources

About